Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercia...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Michael D, Bachmeier, Christina A, Phuoc, Vania H, Chavez, Julio C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987753/
https://www.ncbi.nlm.nih.gov/pubmed/29910620
http://dx.doi.org/10.2147/TCRM.S145039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987753/
https://www.ncbi.nlm.nih.gov/pubmed/29910620
http://dx.doi.org/10.2147/TCRM.S145039

Ejemplares similares